Dianthus Therapeutics, Inc. Common Stock

DNTHNASDAQUSD
85.50 USD
0.50 (0.58%)AT CLOSE (11:59 AM EDT)
85.55
0.03 (0.03%)
POST MARKET (AS OF 06:08 PM EDT)
Post Market
AS OF 06:08 PM EDT
85.55
0.03 (0.03%)
🟢Market: OPEN
Open?$85.53
High?$87.76
Low?$84.75
Prev. Close?$86.00
Volume?1.0M
Avg. Volume?1.4M
VWAP?$85.51
Rel. Volume?0.76x
Bid / Ask
Bid?$74.13 × 100
Ask?$97.69 × 100
Spread?$23.56
Midpoint?$85.91
Valuation & Ratios
Market Cap?4.6B
Shares Out?44.5M
Float?28.8M
Float %?66.7%
P/E Ratio?N/A
P/B Ratio?9.23
EPS?-$3.07
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?13.32Strong
Quick Ratio?13.32Strong
Cash Ratio?1.66Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUED
Score
50/100
P/E?
N/A
P/B?
9.23HIGH
P/S?
2,236.26HIGH
P/FCF?
N/A
EV/EBITDA?
-25.3CHEAP
EV/Sales?
2,211.17HIGH
Returns & Efficiency
ROE?
-32.9%WEAK
ROA?
-30.6%WEAK
Cash Flow & Enterprise
FCF?$-129273000
Enterprise Value?$4.5B
Related Companies
Loading...
News
Profile
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Employees
92
Market Cap
4.6B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2023-09-12
Address
7 TIMES SQUARE
NEW YORK, NY 10036
Phone: 929-999-4055